Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
It is the third rail of Twitter, Maintenance of Certification. But ASN wanted to tackle this head on with a public position and Twitter chat. Take a look at the analytics, storify and transcript.
NephJC has never seen a chat with as many participants or as many tweets,
First tweet was last monday and look at the response! Thanks for getting the word out there!
